In this multicenter phase 1 trial, treatment with IBI343, a CLDN18.2-targeting antibody–drug conjugate, was safe and showed encouraging clinical responses in patients with advanced gastric or gastroesophageal junction adenocarcinoma.
- Jia Liu
- Jianwei Yang
- Lin Shen